Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • How Tangible Assets Are Shaping a New Global Investment Cycle

    Investment Management’s Olga Bitel describes how energy, infrastructure, and industrial investment may shape the next market cycle.

    Read more

  • Asset Allocation: Your Biggest Investment Decision

    Building a portfolio involves countless decisions. But none is more important than how you allocate your wealth across asset classes. This white paper describes the process of developing a customized asset-allocation strategy, achieving meaningful diversification across and within asset classes, and monitoring allocations and reviewing portfolios.

    Read more

  • CEO Perspective: Energy’s Vital Role for Investors and Markets

    Brent Gledhill explores how recent events underscore the centrality of the energy industry and how William Blair’s insight into geopolitical developments, evolving energy systems and infrastructure, and innovative capital can drive long-term investment success.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures